Callan Family Office’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
Callan Family Office's RPRX Position: Q2 2026 in Review
Callan Family Office increased its Royalty Pharma (RPRX) stake by 1.9% in Q2 2026, buying an estimated $12K and bringing the position to 12,107 shares worth $679K. The position accounts for 0.01% of the portfolio, ranked #716.
Callan Family Office first reported a position in RPRX in Q2 2025 and has held it in 4 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.
- Callan Family Office held 12,107 shares of Royalty Pharma worth $679K as of Q2 2026.
- Callan Family Office bought 231 Royalty Pharma shares in Q2 2026, an estimated $12K.
- Royalty Pharma made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #716 holding.
- Callan Family Office first reported a position in Royalty Pharma in Q2 2025 and has held it in 4 quarters since.
- 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.
Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.